Abcam, ab232631, Anti-p18 INK4c/CDKN2C antibody [EPR15891] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal p18 INK4c/CDKN2C antibody. Carrier free. Suitable for IP, WB, ICC/IF, IHC-P and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR15891,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, IP, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232631 is the carrier-free version of
ab192239
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Ion exchange chromatography, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
P18 INK4c also known as CDKN2C is a cyclin-dependent kinase inhibitor that plays an important role in cell cycle regulation. It is a member of the INK4 family and carries a molecular mass of approximately 18 kDa. This protein actively inhibits the activity of CDK4 and CDK6 key kinases that drive the transition from the G1 to S phase in the cell cycle. p18 INK4c is expressed in various tissues with notable expression in the adrenal gland kidney and the nervous system.
Biological function summary
P18 INK4c functions as a regulator by acting as a part of the complex that controls cell proliferation. It ensures that cells do not proceed through the G1/S checkpoint inappropriately maintaining proper cell cycle control. This protein serves as a brake in the cell cycle by binding to CDK4/6 thereby preventing their interaction with D-type cyclins and subsequent cell cycle progression.
Pathways
P18 INK4c is an important component of the retinoblastoma (Rb) pathway as well as the p16INK4a-pRB pathway. These pathways are important for negative regulation of the cell cycle. In these pathways p18 INK4c inhibits CDK4 and CDK6 which are kinases needed to phosphorylate the Rb protein a pivotal step for cell cycle progression. The regulation of these pathways plays a part in processes like cellular senescence and differentiation.
P18 INK4c is associated with various types of cancer including glioma and breast cancer. Alterations in the expression or function of p18 INK4c can lead to unchecked cell proliferation and tumorigenesis. It often interacts with proteins such as CDK4 and CDK6 in these contexts where dysregulation may contribute to the development and progression of the diseases. Understanding p18 INK4c's role could provide insights into potential therapeutic strategies for these cancers.